SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be ...
1,530 active U.S. physicians, representing growth of 27% $2.1 million in trailing 12-month average revenue per territory, representing an increase of 16% New Technology Add-on Payment (“NTAP”) of over ...
SI-Bone took the wraps off its third-quarter numbers just after market close on Monday, divulging that its revenue was $48.7 million for the period. That represented a very healthy year-over-year ...
SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy ...
SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today ...
Spartan Medical® and SI-BONE® announce new partnership to expand access to advanced ultra–minimally invasive treatment options for sacroiliac joint dysfunction ...
Hosted on MSN
SI-BONE, Inc. Reports Strong Q3 2025 Earnings
Si-Bone ((SIBN)) has held its Q3 earnings call. Read on for the main highlights of the call. SI-BONE, Inc. recently held its third-quarter 2025 earnings call, revealing a generally positive sentiment ...
Hosted on MSN
SI-Bone Board Changes and Financial Growth Update
SI-Bone ( (SIBN)) has shared an update. On November 6, 2025, Daniel Wolf resigned from SI-BONE’s Board of Directors, and Thomas A. West was appointed to the Board’s Audit Committee. Despite his ...
The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably. SI-Bone took the wraps off its third-quarter numbers just ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results